News

Results from a clinical trial looking at whether aspirin can prevent heart disease in people with diabetes have recently been reported in the New England Journal of Medicine. The ASCEND trial involved ...

We are thrilled to have more than 5000 patients registered on Add-Aspirin which reflects the hard work and dedication of staff across the UK and India. Over 2300 participants have now been registered ...

The Add-Aspirin Translational Research Manual has recently been updated to v3.0. The manual can be downloaded from the members area of the Add-Aspirin website. Please store a copy in your Investigator Site File and mark V2.0 as ‘superseded’.

Main changes include:

  • Updated contact details (including biobank addresses)
  • Guidance on batch-submission of tumour blocks
  • Addition of the urinary thromboxane sub-study: instructions for urine collection. This only applies to centres who have already been invited to take part.

To centres taking part in the urinary thromboxane sub-study, please await further instructions. You should not start collecting urine until we have been in touch regarding the sub-study launch, which we anticipate to be within the next month.

Please pass this onto the relevant people in your team and don’t hesitate to get in touch if you have any queries.

The Add-Aspirin Delegation Log template has now been updated to include a list of delegated study tasks.

This does not need to be completed retrospectively, but version 3.0 should be used going forward for any new staff joining the trial, or any staff whose study tasks have changed since first completion on the log (for example, a Research Nurse who is now dispensing drug).

Please log in to the members area to download the new template ready for your site file.

New research has suggested that individuals who suffer from both heart failure and type II diabetes may benefit from taking daily aspirin. The study reviewed medical records from more than 12,000 indi ...